drugset
drugset / Trial / NCT04140539

A Clinical Study to Enable Process Validation of Commercial Grade OTL-101

NCT04140539 ↗

Phase 2/3 Withdrawn University of California, Los Angeles
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the current study is to treat at least 3 ADA-SCID patients with OTL-101 prepared by the commercial manufacturing process.

Timeline

Start
2019-10-15
Primary completion
2021-08-30
Completion
2021-08-30

Drugs

EvaluationDrugModalityDoseRoute
Subject SIMOLADAGENE AUTOTEMCEL Unknown — Other

Indications

severe combined immunodeficiency, autosomal recessive, T cell-negative, B cell-negative, NK cell-negative, due to adenosine deaminase deficiency